Rocket Pharmaceuticals Inc RCKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
-
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
-
Rocket Receives FDA Approval for Genetic Immunodeficiency Treatment
-
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
-
Rocket Pharmaceuticals Shares Surge after FDA Accepts Drug Application Resubmission
-
FDA Accepts Rocket Pharmaceuticals' BLA Resubmission for Rare Genetic Disorder Treatment
-
Rocket Pharmaceuticals Pulls FDA Application for RP-L102 Gene Therapy
Trading Information
- Previous Close Price
- $2.70
- Day Range
- $2.53–2.78
- 52-Week Range
- $2.40–5.45
- Bid/Ask
- $2.64 / $2.70
- Shares Outstanding
- 109.17M
- Market Cap
- $289.36M
- Volume/Avg
- 1,314 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.02%
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 202
- Website
- https://www.rocketpharma.com
Valuation
|
Metric
|
RCKT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RCKT
|
|---|---|
Quick Ratio | 5.90 |
Current Ratio | 6.12 |
Interest Coverage | −114.10 |
Quick Ratio
RCKT
Profitability
|
Metric
|
RCKT
|
|---|---|
Return on Assets (Normalized) | −45.56% |
Return on Equity (Normalized) | −53.57% |
Return on Invested Capital (Normalized) | −51.56% |
Return on Assets
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Lshhwvp | Wflcxt | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xynkrtxny | Msjynhj | $65B | |||
| argenx SE ADR
ARGX
| Zwpwllh | Zxd | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lszntwwhw | Bpzgz | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Cqjhtzkt | Rdcsg | $25B | |||
| BioNTech SE ADR
BNTX
| Zkqyftl | Xyfnq | $22B | |||
| Incyte Corp
INCY
| Yxpnmqqb | Txbg | $21B | |||
| Moderna Inc
MRNA
| Xflznfplk | Zndf | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bpnlhqv | Hpy | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Fxbypgwd | Hvy | $13B |
United States